In vision research, the intersection of light and biology exists in a fragile balance. True breakthroughs in biomedical research emerge from sharpened perception—the rare gift of discerning hidden patterns in chaos that elude most eyes..
For Dr. Rahmeh "Ro" Othman, this ability to find meaning in complexity is a defining feature of her work in science and leadership. At Harvard Medical School, she is not only a leader in a new approach to treating inflammatory eye diseases but also in how interdisciplinary biomedical research teams learn to think, work together, and translate scientific discoveries into clinical care.
Reflecting on her work in the lab and the clinic, Dr. Othman says: "I've always loved digging for answers. Being in science stimulates my brain and gives me purpose to advance the field, identify new treatments, and improve patients' lives. Every molecule, if you take time to listen, has a message, and I am motivated by trying to translate those messages into real therapies."
Dr. Othman connects molecular physiology with clinical vision science to uncover biomarkers that can forecast disease even before symptoms appear. Such molecular signals, small lights within the body's vast circuitry, nowadays guide a new generation of ocular therapies, promising to replace invasive injections with non-invasive, precision-targeted treatments.
With over a decade of experience in translational research, spanning immunology, neurobiology, and molecular physiology, she has established a reputation for connecting even the smallest cellular cues to far-reaching clinical relevance. Her science is a form of leadership rooted in curiosity and integrity, where each experiment is inspired by the thought of bringing human suffering to an end.
Fluent in English, French, Arabic, and conversational Italian, and having received training across Lebanon, France, Canada, and the United States, Dr. Othman personifies the global dimension of contemporary biomedicine: it is based on an ethos of empathy; it is evidence-directed; and it unites the conviction that no geography should serve as a block to access innovation.
As light symbolizes perception, it was in Montréal that perception evolved into foresight. At the Université de Montréal, she transformed insight into structure—building experimental standards, mentoring emerging scientists, and shaping a department’s research identity around rigor and collaboration. It was there that her philosophy of science, as a shared dialogue, first took institutional form, transforming curiosity into culture and discovery into direction.
The Foundations of Foresight – Montréal Years
Before she became a leading voice in ocular immunology at Harvard, Dr. Othman was already shaping the foundations of translational science at the Université de Montréal. This period turned technical mastery into leadership.
Her years there marked a shift from learning methods to building frameworks that others would later adopt, establishing her as both a researcher and an institutional bridge-builder.
Dr. Othman’s fascination with the logic of inflammation began much earlier, in the modest laboratories of Lebanon, where she earned both her B.Sc. and M.Sc. in Biochemistry (2008–2012). Working through limited facilities and social unrest, she found purpose in experimentation — a quiet determination to understand how the body heals under pressure.
She recalls: “In Lebanon, meaningful research opportunities were rare. I have spent time in hospital laboratories as a student, which grew my interest and led to an eagerness to conduct experiments myself. After the loss of both parents at a young age, I became independent, and when diabetes began to affect my grandmother's eyesight, the issue became very real. I wanted to trace what was going wrong inside her cells and find a way to prevent it.”
That personal story — watching her grandmother’s vision fade — became both a compass and a catalyst. It transformed empathy into rigor and would later define how Dr. Othman approached mentorship and experimental ethics in Montréal.
Her early research in France and Canada widened that determination into a systemic view of physiology.
At the Université d’Angers, she studied the mechanisms of septic shock and the effects of vasopressors and catecholamines on renal micro- and macrocirculation. This experience would later enable her to bring precision to ocular microsurgery. Moreover, Dr. Othman explored respiratory problems and gastroesophageal reflux in neonatal models at Université de Sherbrooke, uncovering how neural and immune systems interact even in development.
She says: “Every stage of my training — whether in France studying septic shock or in Canada exploring gastroesophageal physiology — taught me how organs respond under stress. Those early lessons in how the body fights to regain balance are what shaped my understanding of inflammation later in the eye.”
These cross-disciplinary experiences forged the systems-thinking that became her signature.
Dr. Othman explains: “Science is inherently interdisciplinary — you can’t study one system or field in isolation and expect to grasp the full picture. My background in respiratory, ocular, and gut systems has shown me that physiology and immunology are part of the same conversation. That attitude enables me to seek new observations and connect discoveries that others might miss.”
When she arrived at the Université de Montréal’s Department of Pharmacology and Physiology, that integrative mindset found its full expression. Her doctoral work on the bradykinin B1 receptor (B1R) and inducible nitric oxide synthase (iNOS) pathways in diabetic retinal inflammation redefined how scientists viewed the eye’s immune circuitry.
Dr. Othman remembers: "This project gave me the confidence to believe that rigorous physiology could lead directly to therapy. It showed that if you truly understand the body's signals, then you could intervene earlier and change the disease process before it became irreversible."
Her 2019 study in Frontiers in Pharmacology demonstrated that blocking the B1R-iNOS axis reversed vascular leakage and oxidative stress. This discovery introduced a new, non-invasive eye-drop model for early diabetic retinopathy.
She explains: “During my Ph.D. I identified a new inflammatory axis in diabetic retinopathy and inhibited it using eye drops. Existing treatments are invasive and don’t address every symptom, but our non-invasive approach reversed inflammation at an early stage. When I later confirmed B1 receptor expression in human eyes, it validated a whole new therapeutic direction.”
Dr. Othman’s follow-up 2020 paper in Pharmaceuticals — part of a special issue honoring bradykinin pioneer Professor Domenico Regoli — confirmed that the same molecular axis held clinical relevance in human retinal tissue.
By 2021, her lead-author publication, “Kinins and Their Receptors as Potential Therapeutic Targets in Retinal Pathologies” (Cells), distilled years of experiments into a coherent translational plan, making kinins and receptors the fulcrum of biomarker-guided therapy in ocular disease.
But her Montréal years were not only about discovery — they were about leadership.
Within the department, Dr. Othman co-led projects on visual cortex plasticity and neuromodulation, bridging neural adaptation with immune signaling, and mentoring early-career researchers on experimental design and integrity. Her collaborators still cite her influence on the department’s ethos.
Dr. Sébastien Talbot, a former Canada Research Chair in Neuro-Immunology and one of Dr. Othman’s long-standing collaborators, credits her with redefining the boundaries of her field: “Few scientists at her stage demonstrate such a combination of scientific insight and experimental precision,” he says.
“Dr. Othman’s mastery of both conceptual design and technical execution makes her expertise highly sought after in the field of inflammation biology. At the Université de Montréal, she established decision-grade standards that became benchmarks for ocular-inflammation research, and the assays and analytical pipelines she designed now form the backbone of multiple laboratories’ work.”
Dr. Talbot adds: “Over my career, I’ve mentored scientists who now hold positions at Harvard, UCSF, Karolinska, and the Pasteur Institute, and Dr. Othman ranks among the very best. Her work consistently translates complex molecular mechanisms into clinically relevant hypotheses — a hallmark of her subject-matter expertise in inflammation biology.”
Those years in Montréal became the crucible where method met mentorship. Under her influence, ocular-inflammation research there evolved from individual experiments into a coordinated framework — proof that leadership in science begins not with authority, but with the discipline to listen, refine, and teach.
